Real-World Experience with Emicizumab Prophylaxis in the Milan Cohort: A Single-Center Experience
Authors: Arcudi Sara , Ciavarella Alessandro , Gualtierotti Roberta , Marino Sonia , Boscarino Marco , Siboni Simona , Biguzzi Eugenia , Schiavone Lucia , Novembrino Cristina , Valsecchi Carla , Peyvandi Flora 
Published: November 2021

INTRODUCTION: Emicizumab is a humanised bispecific monoclonal antibody, which replaces the function of factor VIII (FVIII) by bridging activated factor IX and factor X. Emicizumab is approved for prophylaxis of patients with Hemophilia A (HA), both with and without inhibitors. Real-world data on the efficacy and safety of emicizumab were recently reported from a few hemophilia treatment centers, but more data are needed to assess the efficacy and safety of emicizumab in comparison to standard prophylactic treatment.

OBJECTIVE: To evaluate the safety and efficacy of emicizumab prophylaxis in a single cohort of patients with HA, with and without inhibitors.

METHODS: We performed an observational prospective study including patients affected with HA, with and without inhibitors, switched to emicizumab prophylaxis in the post-marketing era. Data regarding inhibitor status, Annualized Bleeding Rate (ABR), cause of bleeding, type and location of bleeds, Emicizumab Plasmatic Concentration [Emi] and activated partial thromboplastin time (aPTT) were collected for each patient. Hemophilia Joint Health Scores (HJHS) and General Health Visual Analogue Scale (GH-VAS) were collected by trained physiotherapists before switching to emicizumab and 12 months after treatment start.

RESULTS: A total of 22 patients, 21 with severe and 1 with moderate HA, were enrolled. Twenty patients were without inhibitor against FVIII and 2 adults with inhibitor were previously treated with bypassing agents. All patients started emicizumab prophylaxis with a loading dose of 3 mg/kg once weekly for 4 weeks, followed by a maintenance dosage of 1.5 mg/kg weekly. Within the children cohort, 3 were Previously Untreated Patients (PUPs) and 2 were previously treated with FVIII without developing inhibitor. The ABR showed a reduction of 74% in the entire cohort, as reported in Table 1. When stratifying for age groups, the ABR reduction was 70% for adults and 100% for children. Within the adults, the zero-bleeding patients increased from 2 to 11 patients (from 12 to 64%, respectively). In the adult cohort, 6 patients experienced 11 bleeding events over a mean follow-up of 300 days. Five out of 11 events were experienced in 6 months by a single patient who developed anti-drug antibodies (ADA) against emicizumab around the 5 th week ([Emi] 31.7 ug/ml). The prophylaxis with emicizumab was interrupted due to the treatment failure, which occurred despite spontaneous ADA clearance. Another patient developed ADA around the 9 th week ([Emi] 28.3 ug/ml), but without associated bleedings in up to 14 weeks of follow-up (minimum [Emi] 17 ug/ml). Of the remaining 5 adults who experienced bleedings during emicizumab prophylaxis, one patient developed spontaneous soft tissue bleeding, another one developed a spontaneous hemarthrosis in his target joint and the remaining 3 patients experienced post-traumatic joint bleedings, 2 out of 3 bleedings were in target joints. The analysis of the number of total joint bleedings before and after switching stratified for spontaneous and post-traumatic, revealed a reduction in target joint bleedings of 73% and a reduction of spontaneous and post-traumatic bleeding of 80% and 43%, respectively. All events were managed in outpatient clinic and required only a single infusion of FVIII concentrate. The plasmatic concentrations of emicizumab at steady state were within previous reported normal range for all patients, with exception of the two patients who developed ADA. Interestingly, steady state concentration was higher in children than in adults (median [Emi] 64.9 ug/ml and 49.85, respectively). The HJHS and GH-VAS scores at baseline and after 12 months of emicizumab prophylaxis available in 6 adults showed improvement in joint health and self-perceived global health, as shown in Figures 2 and 3. No thrombotic events were reported in the entire cohort.

DISCUSSION: We report our Milan single center experience on the use of emicizumab prophylaxis in children and adults with HA, with and without inhibitors. Our experience shows a good efficacy of emicizumab both in children and adults, with few post-traumatic bleedings occurring mainly in target joints of adult patients. In addition, physician's and self-assessed scores revealed an improvement of patient's joint health after 12 months of emicizumab prophylaxis.

Figure 1 Figure 1.

Disclosures

Peyvandi: Roche: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Sobi: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria.